2. Anti-infection
  3. Reverse Transcriptase HIV
  4. Elvucitabine

Elvucitabine is an L-nucleoside analogue. Elvucitabine is a potent nucleoside reverse transcriptase (RT) inhibitor. Elvucitabine can be used in research of viral infection.

For research use only. We do not sell to patients.

Elvucitabine

Elvucitabine Chemical Structure

CAS No. : 181785-84-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Elvucitabine Related Antibodies

Top Publications Citing Use of Products

View All HIV Isoform Specific Products:

View All Isoforms
HIV HIV-1 HIV-2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Elvucitabine is an L-nucleoside analogue. Elvucitabine is a potent nucleoside reverse transcriptase (RT) inhibitor. Elvucitabine can be used in research of viral infection[1].

Cellular Effect
Cell Line Type Value Description References
B16 IC50
> 200 μM
Compound: 1
In vitro inhibitory activity against growth of HIV infected B16 cell line
In vitro inhibitory activity against growth of HIV infected B16 cell line
[PMID: 9873711]
CCRF-CEM ED50
7 μM
Compound: 2
In vitro concentration required to inhibit 50% of CEM cell growth
In vitro concentration required to inhibit 50% of CEM cell growth
[PMID: 8627596]
CCRF-CEM ED50
> 100 μM
Compound: 2
In vitro concentration required to decrease 50% of mitochondrial DNA content in CEM cells
In vitro concentration required to decrease 50% of mitochondrial DNA content in CEM cells
[PMID: 8627596]
CCRF-CEM IC50
0.46 μM
Compound: beta-L-D4FC
Tested in vitro for anticancer activity against CEM cells
Tested in vitro for anticancer activity against CEM cells
[PMID: 10072683]
CCRF-CEM IC50
13 μM
Compound: 4
Tested for cytotoxicity in human T-cell lymphoblastic leukemia cell line (CEM)
Tested for cytotoxicity in human T-cell lymphoblastic leukemia cell line (CEM)
[PMID: 9871628]
CCRF-CEM IC50
24 μM
Compound: 1
In vitro inhibitory activity against growth of HIV infected CEM cells combined with murine CTLL-2T lymphoblast cell line
In vitro inhibitory activity against growth of HIV infected CEM cells combined with murine CTLL-2T lymphoblast cell line
[PMID: 9873711]
CCRF-CEM IC50
6.5 μM
Compound: 1
In vitro inhibitory activity against growth of HIV infected CEM cell line
In vitro inhibitory activity against growth of HIV infected CEM cell line
[PMID: 9873711]
CCRF-CEM IC50
> 100 μM
Compound: RVT
Cytotoxicity was determined in CEM cells, relative to RVT
Cytotoxicity was determined in CEM cells, relative to RVT
[PMID: 15081000]
DLD-1 IC50
> 200 μM
Compound: 1
In vitro inhibitory activity against growth of HIV infected DLD-1 cell line
In vitro inhibitory activity against growth of HIV infected DLD-1 cell line
[PMID: 9873711]
HepG2 EC50
17 nM
Compound: 4
Tested for effective concentration against HBV treated with drug every 3 days for 9 days using human hepatoblastoma cell line HepG2 2.2.15
Tested for effective concentration against HBV treated with drug every 3 days for 9 days using human hepatoblastoma cell line HepG2 2.2.15
[PMID: 9871628]
HepG2 ED50
2 nM
Compound: 2
Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line
Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line
[PMID: 8627596]
HepG2 ED50
2 nM
Compound: 2
Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line
Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line
[PMID: 8627596]
HepG2 IC50
118 μM
Compound: beta-L-D4FC
Tested in vitro for anticancer activity against HepG2 cells
Tested in vitro for anticancer activity against HepG2 cells
[PMID: 10072683]
HepG2 IC50
> 200 μM
Compound: 1
In vitro inhibitory activity against growth of HIV infected HepG2 cell line
In vitro inhibitory activity against growth of HIV infected HepG2 cell line
[PMID: 9873711]
LNCaP IC50
55.2 μM
Compound: beta-L-D4FC
Tested in vitro for anticancer activity against LNCaP cells
Tested in vitro for anticancer activity against LNCaP cells
[PMID: 10072683]
MCF7 IC50
82.8 μM
Compound: beta-L-D4FC
Tested in vitro for anticancer activity against MCF-7 cells
Tested in vitro for anticancer activity against MCF-7 cells
[PMID: 10072683]
MT2 ED50
0.09 μM
Compound: 2
Concentration required to inhibit 50% of HIV activity in MT-2 cells
Concentration required to inhibit 50% of HIV activity in MT-2 cells
[PMID: 8627596]
MT2 IC50
9 μM
Compound: 1
In vitro inhibitory activity against growth of HIV infected MT-2/IIIB cell line
In vitro inhibitory activity against growth of HIV infected MT-2/IIIB cell line
[PMID: 9873711]
PC-3 IC50
> 100 μM
Compound: beta-L-D4FC
Tested in vitro for anticancer activity against PC-3 cells
Tested in vitro for anticancer activity against PC-3 cells
[PMID: 10072683]
Rat1 IC50
> 200 μM
Compound: 1
In vitro inhibitory activity against growth of HIV infected Rat-1 cell line
In vitro inhibitory activity against growth of HIV infected Rat-1 cell line
[PMID: 9873711]
SK-MEL-28 IC50
> 100 μM
Compound: beta-L-D4FC
Tested in vitro for anticancer activity against SK-MEL-28 cells
Tested in vitro for anticancer activity against SK-MEL-28 cells
[PMID: 10072683]
SK-MES-1 IC50
99.1 μM
Compound: beta-L-D4FC
Tested in vitro for anticancer activity against SK-MES-1 cells
Tested in vitro for anticancer activity against SK-MES-1 cells
[PMID: 10072683]
Vero IC50
9.4 μM
Compound: beta-L-D4FC
Tested in vitro for cytotoxicity against Vero cells
Tested in vitro for cytotoxicity against Vero cells
[PMID: 10072683]
Vero IC50
> 100 μM
Compound: RVT
Cytotoxicity was determined in Vero cells, relative to RVT
Cytotoxicity was determined in Vero cells, relative to RVT
[PMID: 15081000]
Clinical Trial
Molecular Weight

227.19

Formula

C9H10FN3O3
CAS No.
SMILES

O=C1N=C(C(F)=CN1[C@H]2O[C@H](C=C2)CO)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Elvucitabine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Elvucitabine181785-84-2Reverse TranscriptaseHIVHuman immunodeficiency virusL-nucleoside analogueviral infectionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Elvucitabine
Cat. No.:
HY-117582
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.